Quintet Private Bank Europe S.A. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,496 shares of the medical research company's stock after acquiring an additional 2,242 shares during the quarter. Thermo Fisher Scientific makes up 2.2% of Quintet Private Bank Europe S.A.'s portfolio, making the stock its 11th biggest position. Quintet Private Bank Europe S.A.'s holdings in Thermo Fisher Scientific were worth $37,069,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. RMR Wealth Builders raised its holdings in shares of Thermo Fisher Scientific by 18.2% during the first quarter. RMR Wealth Builders now owns 2,869 shares of the medical research company's stock valued at $1,428,000 after acquiring an additional 442 shares in the last quarter. NorthCrest Asset Manangement LLC raised its holdings in shares of Thermo Fisher Scientific by 2.6% during the first quarter. NorthCrest Asset Manangement LLC now owns 53,885 shares of the medical research company's stock valued at $26,813,000 after acquiring an additional 1,354 shares in the last quarter. Sky Investment Group LLC raised its holdings in Thermo Fisher Scientific by 1.2% in the first quarter. Sky Investment Group LLC now owns 18,295 shares of the medical research company's stock worth $9,104,000 after purchasing an additional 223 shares in the last quarter. Parkside Investments LLC raised its holdings in Thermo Fisher Scientific by 1.1% in the first quarter. Parkside Investments LLC now owns 14,528 shares of the medical research company's stock worth $7,229,000 after purchasing an additional 161 shares in the last quarter. Finally, Thomasville National Bank raised its holdings in Thermo Fisher Scientific by 554.1% in the first quarter. Thomasville National Bank now owns 19,956 shares of the medical research company's stock worth $9,930,000 after purchasing an additional 16,905 shares in the last quarter. Institutional investors own 89.23% of the company's stock.
Insiders Place Their Bets
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Stock Performance
Shares of Thermo Fisher Scientific stock traded down $13.21 during trading on Friday, hitting $402.12. 2,384,678 shares of the company's stock traded hands, compared to its average volume of 1,931,788. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The stock has a market capitalization of $151.80 billion, a P/E ratio of 24.33, a PEG ratio of 2.99 and a beta of 0.78. The business has a 50-day simple moving average of $416.80 and a 200-day simple moving average of $492.19.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the firm posted $5.11 earnings per share. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific's payout ratio is 10.09%.
Analyst Ratings Changes
A number of equities analysts have issued reports on TMO shares. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Scotiabank decreased their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a report on Friday, April 25th. Barclays decreased their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Robert W. Baird reduced their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $605.30.
View Our Latest Stock Report on TMO
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
